Master Alliance Provisions Guide (MAPGuide)

Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement

  • Equitable Access | Ensuring continuity

<p><strong><span style=”textdecoration: underline;”>13. Term and Terminationspan>strong>p>
<p><b>13.5 Public Health License. b><span style=”fontweight: 400;”>Without prejudice to Clauses 13.1 to 13.4, in the event of a material breach by Novavax of any of its material obligations under this Agreement, provided that (i) the material breach is not capable of remedy; or (ii) the material breach is not remedied within [***] after being given written notice by Gavi requiring such remedy, such breach shall constitute aPublic Health License Triggerpursuant to span><span style=”textdecoration: underline;”><a href=”” target=”_blankrel=”noopener“><span style=”fontweight: 400;”>clause 13.5(c) of the CEPI Funding Agreementspan>a>span><span style=”fontweight: 400;”>. CEPI shall have the benefit of and may in its own right enforce the provisions of this Clause subject to, and in accordance with, the Contracts (Rights of Third Parties) Act 1999, and shall be entitled to exercise its rights under clause 13 of the CEPI Funding Agreement, provided the additional conditions set out in clauses 13.4(a) and (b) therein are also met.span>p>